CD47 and neoplasm: Based on these concepts, Zhang et al. [97] developed a PLGA-based delivery system for an anti CD47 siRNA (siCD47), combined with the drug mitoxantrone (MTO) that can induce CRT exposure on the surface of tumor cells.